Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Herve Ghesquieres, Corinne Haioun, Hervé Tilly, Jean-Philippe Jais, Fabrice Jardin

Blood (2024) 144 (Supplement 1): 649.

https://doi.org/10.1182/blood-2024-203926

Published: 2024

Journal Articles

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Jean-Marie Michot, Cédric Portugues, Lucie Oberic, Fabrice Jardin, Vincent Delwail, Vincent Camus, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Frederic Peyrade, Hervé Tilly

Blood (2024) 144 (Supplement 1): 4467.

https://doi.org/10.1182/blood-2024-202588

Published: 2024

Journal Articles

Aberrant Isotype Class Switch Recombination Reactivation Leads to a Genome Wide Genomic Instability in Follicular Lymphoma

Mathieu Viennot, Marion Chanussot-Godey, Vinciane Rainville, Sandrine Le Noir, Melody Caillot, Fanny Drieux, Elena-Liana Veresezan, Roman Vion, Pierre-Julien Viailly, Vincent Camus, Hervé Tilly, Eric Pinaud, Fabrice Jardin, Philippe Ruminy

Blood (2024) 144 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2024-203479

Published: 2024

Journal Articles

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Blood (2024) 144 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2024-193960

Published: 2024

Journal Articles

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Blood (2024) 144 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2024-209815

Published: 2024

Journal Articles

Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

Blood (2024) 144 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2024-194387

Published: 2024

Journal Articles

CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2024-205388

Published: 2024

Journal Articles

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Vincent Camus, Pierre Sesques, Alessio Bruscaggin, Daphne Krzisch, Mathieu Viennot, Luc-Matthieu Fornecker, Morgane Cheminant, Sébastien Bailly, Franck Morschhauser, Pierre Feugier, Sylvain Choquet, Eric Durot, Sylvain Carras, Caroline Delette, Gandhi Damaj, Agathe Waultier-Rascalou, Pierre Lebreton, Katell Le Du, Krimo Bouabdallah, Roch Houot, Stéphane Vigouroux, Kamel Laribi, Laure Lebras, Lucie Oberic, Sandy Amorim, Simone Bocchetta, Pierre-Julien Viailly, Vinciane Rainville, Philippe Ruminy, Melody Caillot, Lodovico Terzi Di Bergamo, Georgia Alice Galimberti, Maria Cristina Pirosa, Matin Salehi, Gabriela Forestieri, Fanny Drieux, Elena-Liana Veresezan, Alexandra Traverse-Glehen, Marie Donzel, Emilie Leveque, Lucie Burel, Elodie Bohers, Marie-Delphine Lanic, Pascaline Etancelin, Stéphanie Becker, Pierre Decazes, David Tonnelet, Simon Draye-Carbonnier, Hervé Tilly, Fabrice Jardin, Davide Rossi

Blood (2024) 144 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2024-202508

Published: 2024

Journal Articles

Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation

Vincent Camus, Mathieu Viennot, Victor Bobée, Pierre-Julien Viailly, Elodie Bohers, Vinciane Rainville, Marie-Delphine Lanic, Elena-Liana Veresezan, Fanny Drieux, Emilie Leveque, Pascaline Etancelin, Dominique Penther, Hervé Tilly, Alexandra Zduniak, Philippe Ruminy, Fabrice Jardin

Blood (2024) 144 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2024-200543

Published: 2024

Journal Articles

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 3129.

https://doi.org/10.1182/blood-2024-203186

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Fabrice Jardin, Vibha Raghavan, Samuel Tracy, Sandhya Balasubramanian, Laurie H. Sehn, Christopher R. Flowers, Franck Morschhauser, Alex F. Herrera, Marek Trněný, Jeff P. Sharman, Gilles Salles, Hervé Tilly, Jonathan W. Friedberg, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Georg Lenz

Blood (2023) 142 (Supplement 1): 169.

https://doi.org/10.1182/blood-2023-178564

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Xavier Phina-Ziebin, Emmanuel Bachy, Francois Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques-Olivier Bay, Sylvain Carras, Pierre Bories, René-Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Elodie Gat, Julien Calvani, Marie Parrens, Elsa Poullot, Alexandra Traverse-Glehen, Louise Roulin

Blood (2023) 142 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2023-180707

Published: 2023

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

Journal Articles

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Herve Ghesquieres, Frederic Peyrade, Fabrice Jardin, Stephanie Guidez, Fontanet Delices Bijou, Pierre Sesques, Cédric Rossi, Luc Matthieu Fornecker, Ludovic Fouillet, Sylvain Carras, Benoit Tessoulin

Blood (2023) 142 (Supplement 1): 72.

https://doi.org/10.1182/blood-2023-177708

Published: 2023

Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood (2023) 142 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2023-178623

Published: 2023

NARROW

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Aberrant Isotype Class Switch Recombination Reactivation Leads to a Genome Wide Genomic Instability in Follicular Lymphoma

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only